Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | LIPE | Q05469 | 2/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5938227 | 1.00 | NR1H2 (0.50) | NR1H2LIPEDDB1CRBNUSP30 | |
| SCHEMBL22784207 | 1.00 | NR1H2 (0.50) | NR1H2LIPEDDB1CRBNUSP30 | |
| SCHEMBL43653 | 1.00 | NR1H2 (0.50) | NR1H2LIPEDDB1CRBNUSP30 | |
| SCHEMBL29560774 | 1.00 | NR1H2 (0.50) | NR1H2LIPEDDB1CRBNUSP30 | |
| SCHEMBL29965040 | 0.93 | LIPE (0.45) | NR1H2LIPEDDB1CRBNUSP30 | |
| SCHEMBL14239659 | 0.91 | NR1H2 (0.48) | NR1H2LIPEDDB1CRBNUSP30 | |
| SCHEMBL1692080 | 0.91 | NR1H2 (0.48) | NR1H2LIPEDDB1CRBNUSP30 | |
| SCHEMBL5940329 | 0.86 | NR1H2 (0.54) | NR1H2LIPEDDB1CRBNUSP30 | |
| SCHEMBL5938643 | 0.86 | NR1H2 (0.54) | NR1H2LIPEDDB1CRBNUSP30 | |
| SCHEMBL14239632 | 0.84 | NR1H2 (0.52) | NR1H2LIPEDDB1CRBNUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119156393-A | Cyclic compound, preparation method and medical application thereof | 翰森生物有限责任公司 | 2024-12-17 | — | — | CN | disclosed |
| EP-3703680-B1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNIV VANDERBILT (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023208005-A1 | CYCLIC COMPOUNDS, PREPARATION METHODS AND MEDICINAL USES THEREOF | HANSOH BIO LLC (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11780839-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| US-11352344-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352344-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2022-06-07 | — | — | US | disclosed |
| EP-3773552-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20200339547-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2020-10-29 | — | — | US | disclosed |
| US-20100261773-A1 | 3.3.0 BICYCLIC GlyT1 INHIBITORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2010-10-14 | — | — | US | disclosed |
| US-20100261773-A1 | 3.3.0 BICYCLIC GlyT1 INHIBITORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2010-10-14 | — | — | US | disclosed |
| US-20100261773-A1 | 3.3.0 BICYCLIC GlyT1 INHIBITORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2010-10-14 | — | — | US | disclosed |
| WO-2010068851-A1 | 3.3.0 BICYCLIC GLYT1 INHIBITORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSTIY (US) | 2010-06-17 | — | — | WO | disclosed |
| EP-1796663-A4 | TRICYCLIC HETEROARYL PIPERAZINES, PYRROLIDINES AND AZETIDINES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090069365-A1 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | BENNANI YOUSSEF L | 2009-03-12 | — | — | US | disclosed |
| US-7423056-B2 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | ATHERSYS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1796663-A2 | TRICYCLIC HETEROARYL PIPERAZINES, PYRROLIDINES AND AZETIDINES AS SEROTONIN RECEPTOR MODULATORS | Athersys, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20060079567-A1 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | ATHERSYS, INC. | 2006-04-13 | — | — | US | disclosed |
| WO-2006028961-A2 | TRICYCLIC HETEROARYL PIPERAZINES, PYRROLIDINES AND AZETIDINES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079567-A1 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | HTR5A, HTR2C, HTR2A | NR1H2 981/4885LIPE 922/4885DDB1 4119/4885 |
| US-20100261773-A1 | 3.3.0 BICYCLIC GlyT1 INHIBITORS AND METHODS OF MAKING AND USING SAME | SLC7A1, SLC1A1, SLC5A1 | NR1H2 1235/4885LIPE 2526/4885DDB1 1674/4885 |
| US-20200339547-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM3, CHRM4 | NR1H2 455/4885LIPE 1959/4885DDB1 4071/4885 |
| US-11352344-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM3, CHRM4 | NR1H2 341/4885LIPE 2068/4885DDB1 4093/4885 |
| US-20090069365-A1 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | HTR5A, HTR2C, HTR2A | NR1H2 981/4885LIPE 922/4885DDB1 4119/4885 |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, HDAC6 | NR1H2 417/4885LIPE 1956/4885DDB1 3049/4885 |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | MLLT1, BMI1, MEN1 | NR1H2 3177/4885LIPE 3833/4885DDB1 775/4885 |
| US-11780839-B2 | Compounds for treating Huntington's disease | HTT, HYPK, HDAC6 | NR1H2 417/4885LIPE 1956/4885DDB1 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.